Sulphasalazine and derivatives, natural killer activity and ulcerative colitis
- PMID: 2866061
- DOI: 10.1042/cs0690177
Sulphasalazine and derivatives, natural killer activity and ulcerative colitis
Abstract
The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), sulphapyridine and azodisalicylic acid (ADS) in vitro on the natural killer (NK) activity of peripheral blood mononuclear cells (MNC) have been examined and compared with those of the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA) and the cyclooxygenase inhibitor, indomethacin. Sulphasalazine, sulphapyridine and ADS inhibited NK activity with 50% inhibitory concentrations (IC50) of 0.7, 2.5 and 4.0 mmol/l respectively. The effect was rapidly reversible. In contrast, 5-ASA minimally inhibited NK activity at 50 mmol/l only. NDGA potently inhibited NK activity (IC50 27 mumol/l) but this was only partly reversible in short term incubations. Indomethacin had no effect at concentrations less than those inhibiting cyclo-oxygenase activity (1-10 mumol/l) but potently and reversibly inhibited NK activity at or above 25 mumol/l. The inhibitory effects observed were unlikely to be due to direct toxicity of effector cells as 5-ASA, sulphapyridine and ADS had no effect on the viability of peripheral blood MNC, whereas NDGA and indomethacin lysed MNC only at maximal concentrations tested. Though sulphasalazine produced MNC lysis at and above 1 mmol/l, the rapid reversibility of the inhibition of NK activity at 1 mmol/l suggested that lysis of NK cells contributed little to the suppressive effect at this concentration. The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. Any inhibitory effect on cellular immune function of indomethacin does not necessarily reflect an effect of cyclo-oxygenase inhibition.
Similar articles
-
Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.Gut. 1990 Sep;31(9):1030-2. doi: 10.1136/gut.31.9.1030. Gut. 1990. PMID: 1976576 Free PMC article. Clinical Trial.
-
Inhibition of leucocyte motility by drugs used in ulcerative colitis.Gut. 1981 Aug;22(8):642-7. doi: 10.1136/gut.22.8.642. Gut. 1981. PMID: 6116649 Free PMC article.
-
Increased suppressor cell activity in inflammatory bowel disease.Gut. 1981 Dec;22(12):1025-30. doi: 10.1136/gut.22.12.1025. Gut. 1981. PMID: 6119275 Free PMC article.
-
Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?Br J Rheumatol. 1995 Nov;34 Suppl 2:16-9. Br J Rheumatol. 1995. PMID: 8535642 Review.
-
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001. Clin Pharmacokinet. 1985. PMID: 2864155 Review.
Cited by
-
Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.Gut. 1993 Jun;34(6):788-93. doi: 10.1136/gut.34.6.788. Gut. 1993. PMID: 8100205 Free PMC article.
-
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.Drugs. 1989 Aug;38(2):267-88. doi: 10.2165/00003495-198938020-00007. Drugs. 1989. PMID: 2670519 Review.
-
Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.Gut. 1992 Jan;33(1):59-64. doi: 10.1136/gut.33.1.59. Gut. 1992. PMID: 1740279 Free PMC article.
-
Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.Gut. 1990 Sep;31(9):1030-2. doi: 10.1136/gut.31.9.1030. Gut. 1990. PMID: 1976576 Free PMC article. Clinical Trial.
-
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Gut. 2000 Sep;47(3):410-4. doi: 10.1136/gut.47.3.410. Gut. 2000. PMID: 10940280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources